

| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 5mg | 180 pills | €2.61 | €521.55 €469.40 Best Price | |
| 5mg | 120 pills | €2.73 | €364.02 €327.62 | |
| 5mg | 90 pills | €2.93 | €292.54 €263.29 | |
| 5mg | 60 pills | €3.10 | €206.49 €185.85 | |
| 5mg | 30 pills | €3.81 | €127.07 €114.36 | |
| 10mg | 180 pills | €3.65 | €729.38 €656.44 Popular | |
| 10mg | 120 pills | €4.00 | €533.47 €480.12 | |
| 10mg | 90 pills | €4.13 | €413.00 €371.70 | |
| 10mg | 60 pills | €4.19 | €279.30 €251.37 | |
| 10mg | 30 pills | €4.65 | €154.87 €139.38 |
Disclaimer: This page provides general information about Vesicare (solifenacin) and its use. It is not a substitute for professional medical advice. For personal guidance, consult a doctor or pharmacist in Ireland.
Vesicare is a prescription medicine containing solifenacin. It is an antimuscarinic (anticholinergic) drug used to reduce the bladder’s involuntary contractions. The primary aim is to lessen urgency, frequency, and urge incontinence in adults with overactive bladder.
Solifenacin acts on receptors in the bladder to relax the detrusor muscle during the storage phase of the bladder cycle. By doing so, it helps the bladder hold more urine and diminishes sudden urges to urinate. The medicine is typically taken once daily, and doctors consider it when symptoms significantly affect daily life or quality of sleep and activity.
In Ireland, Vesicare is generally prescribed after discussion of symptoms, medical history, and other treatment options. A healthcare professional will assess whether the benefits are likely to outweigh potential risks, including side effects or interactions with other medicines. Always follow the specific advice given by your prescriber and the patient information leaflet that accompanies the product.
Vesicare is primarily used for adults with overactive bladder who experience frequent, sudden urges to urinate, sometimes with leakage. It is one option among several medicines that target bladder control. Doctors weigh symptom severity, impact on daily life, and existing health conditions to decide whether Vesicare is suitable.
When selecting a treatment, clinicians consider factors such as how bothersome the symptoms are, how often they occur, and how well a patient tolerates drug effects. Alternatives may include different antimuscarinics or non-antimuscarinic therapies. The choice can hinge on prior responses to similar medicines, the risk profile for side effects like dry mouth or constipation, and patient preference regarding dosing frequency and convenience.
Ongoing monitoring is common after starting Vesicare. If symptoms persist or side effects are troublesome, a clinician may adjust the plan—either by changing to another medication, adjusting the dose, or adding nonpharmacological approaches such as bladder training or pelvic floor exercises. In case of kidney or liver impairment, or if you take other medicines with potential interactions, a healthcare professional will review whether Vesicare remains appropriate.
Vesicare belongs to the antimuscarinic class. It blocks muscarinic receptors in the bladder, which reduces the excitability of the detrusor muscle during the storage phase. This results in lower bladder pressure during filling and fewer sudden urges to urinate. The effect helps to improve symptoms over time, with some patients noticing improvement within the first weeks of therapy.
Compared with some older antimuscarinics, Vesicare is often described as having a bladder-focused action profile, which can mean fewer systemic effects for many people. It is taken once daily, which supports adherence for some patients who prefer a simple regimen. Other medicines in the same broad class may differ in receptor subtype affinity, duration of action, and side-effect profile, leading clinicians to tailor therapy to a patient’s needs and tolerability.
Differences from other drug classes are notable: for instance, beta-3 agonists work by a different mechanism and may be chosen when antimuscarinics cause troublesome side effects or are not effective. The choice between Vesicare and other options such as alternative antimuscarinics depends on symptom pattern, prior responses, and individual risk factors. Always discuss the rationale for a chosen therapy with your clinician if you have questions.
The table below offers a concise snapshot of Vesicare alongside two well-known alternatives. It highlights the primary use, typical onset of symptom relief, and a key advantage of each option. This is educational information and not a recommendation.
| Name | Primary Use | Typical Onset | Key Advantage |
|---|---|---|---|
| Vesicare (solifenacin) | Overactive bladder symptoms in adults | Symptom relief may begin within weeks; full effect develops over time | Once-daily dosing with targeted bladder effects; may have a tolerability profile suitable for some patients |
| oxybutynin (Ditropan) | Overactive bladder and certain bladder conditions | Symptoms may improve over weeks | Often widely studied; can be available in multiple formulations |
| tolterodine (Detrusitol) | Overactive bladder symptoms | Symptom improvement typically over days to weeks | Balanced efficacy with a side-effect profile that some patients tolerate well |
| mirabegron (Myrbetriq) | Overactive bladder symptoms; beta-3 agonist option | Often provides gradual relief over weeks | Different mechanism may lead to fewer anticholinergic side effects for some people |
Take Vesicare exactly as prescribed by your doctor. Most people take it once daily, with or without food. Do not split, crush, or chew the tablets; swallow them whole with water.
If you miss a dose, take it as soon as you remember unless it is near the time of your next dose. Do not double up to make up for a missed dose. Avoid drinking excessive alcohol, which can worsen side effects such as dizziness or drowsiness.
Keep track of how you feel after starting Vesicare. If you have underlying health conditions, such as kidney or liver issues, or if you take other medicines, tell your pharmacist or doctor. Store the medicine as advised on the packaging and keep it out of reach of children. If you are pregnant, planning pregnancy, or breastfeeding, discuss the risks and benefits with your clinician before using Vesicare.
Common side effects reported with Vesicare include dry mouth, constipation, blurred vision, and dizziness. Some people may experience upset stomach, dry eyes, or mild sleepiness. If these effects are bothersome or persist, speak with a healthcare professional to review your plan.
Serious adverse reactions are less common but require urgent medical attention. Seek help promptly if you notice severe allergic reactions, signs of urinary retention (inability to pass urine), severe dizziness, fainting, or vision changes that worsen. People with specific conditions may be advised against Vesicare, such as those with urinary retention, certain types of glaucoma, severe kidney or liver disease, or a known intolerance to solifenacin or related drugs.
Contraindications and cautions: inform your clinician about all medications you use, including over-the-counter products and supplements. People with multiple health conditions or who are older may have higher sensitivity to antimuscarinic effects, such as confusion, memory issues, or pronounced dry mouth. A pharmacist or doctor will tailor advice to your situation and ensure safe use alongside other therapies.
Vesicare can interact with other medicines that have antimuscarinic effects, potentially increasing side effects like dry mouth or constipation. Inform your healthcare provider about all prescriptions, non-prescription medicines, and supplements you take to avoid interactions.
Some medicines that affect liver enzymes or kidney function may alter solifenacin levels in the body. This can change how Vesicare works or its tolerability. It is important to review all medicines with your clinician, especially if you start or stop a drug that can influence metabolism.
Alcohol and other central nervous system depressants can enhance dizziness or sedation when used with Vesicare. Discuss your plans for alcohol use with your clinician, particularly if you notice drowsiness or impaired coordination after starting therapy.
When deciding between Vesicare and alternatives, priorities may include the balance of symptom relief and the risk of side effects, dosing convenience, and personal preference regarding how a drug impacts daily activities. For some people, a beta-3 agonist offers a different side-effect profile, while others prefer an antimuscarinic for stronger deterrence of bladder contractions.
Individual health status matters. Patients with cognitive concerns, a high burden of anticholinergic medications, or certain eye conditions may be steered toward or away from Vesicare depending on risk factors and overall treatment goals. Always have a detailed discussion with your clinician about what to expect, how to monitor response, and when to reassess therapy.
In Ireland, access to Vesicare and alternatives is guided by local prescribing rules and professional judgment. If you have questions about whether Vesicare fits your condition, your GP or specialist can help interpret symptoms, review medical history, and plan a tailored treatment approach.
Switching is common when symptoms persist or side effects are difficult to tolerate. A clinician will consider your previous responses, current health, and other medications before recommending a change. Always consult your doctor before stopping or starting a new antimuscarinic.
The term “better” depends on individual factors. Vesicare may offer a different side-effect profile and once-daily dosing, while oxybutynin has a longer history of use and comes in multiple formulations. A clinician will weigh symptom control, tolerability, and patient preference when comparing options.
Generic availability depends on regulatory approvals and market introductions. If a generic solifenacin is approved, a pharmacist or doctor can confirm whether it is appropriate for you and discuss any differences in formulation or cost with you.
The choice depends on patient factors and tolerance. Vesicare is an antimuscarinic and may be preferred when there is a desire to avoid beta-3–mediated mechanisms or when a patient has tolerated similar medicines well in the past. Mirabegron offers a different mechanism and a distinct side-effect profile, which some patients find advantageous.
Safety in pregnancy and lactation requires careful evaluation. If you are or plan to become pregnant, or if you are breastfeeding, discuss Vesicare with your clinician to understand potential risks and alternatives.
If you miss a dose, take it as soon as you remember unless it is close to your next scheduled dose. Do not double the dose to catch up. If you are unsure what to do, contact your pharmacist or clinician for guidance tailored to your treatment plan.
Some people notice improvements in bladder symptoms within a few weeks, while others may take longer. Treatment response can depend on individual factors and concurrent therapies. If there is insufficient improvement after several weeks, consult a clinician to review the plan.
Alcohol can amplify dizziness or sedation in some individuals. Use caution and discuss alcohol use with your clinician, especially if you notice increased drowsiness or impairment after taking Vesicare.
Some people experience dizziness or blurred vision, particularly when starting therapy. If you feel lightheaded or unsteady, avoid driving or operating heavy machinery until you know how the medicine affects you. Seek medical advice if these symptoms persist.
For detailed information, read the official patient information leaflet that accompanies Vesicare. Your pharmacist can explain how to take the medicine, what to expect, and how to manage side effects. Your doctor can answer questions about how Vesicare fits with your medical history, other treatments, and long‑term bladder health goals.
In Ireland, ongoing consultation with a GP or urology specialist is recommended to review symptoms, monitor response to therapy, and consider non-drug strategies such as bladder training or pelvic floor exercises as part of a comprehensive management plan.
14–21 days. Free from €171.67 .
5–9 days. €25.75
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
